Dendreon (NASDAQOTH: DNDNQ ) shares soared on Friday, thanks to an incredibly bullish upgrade by Wall Street, with a price target essentially doubling Thursday's close. Fool health-care analyst David Williamson takes investors through the causes for Sanford Bernstein's sudden change in tone, and what it means for Dendreon.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status, before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company, and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.